Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2007 1
2009 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 1
2017 3
2018 7
2019 3
2020 5
2021 3
2022 6
2023 5
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Synthesis of Spiro[indole-3,3'-pyrrolidine]-2'-(thi)ones.
Yasui M, Ohbu H, Ishikawa M, Yoshida T, Takeda N, Hirao S, Abe T, Ueda M. Yasui M, et al. Among authors: ishikawa m. J Org Chem. 2023 Jan 20;88(2):1093-1106. doi: 10.1021/acs.joc.2c02561. Epub 2022 Dec 28. J Org Chem. 2023. PMID: 36576873
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.
Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H. Naoe T, et al. Among authors: ishikawa m. Cancer Immunol Immunother. 2023 Aug;72(8):2865-2871. doi: 10.1007/s00262-023-03432-4. Epub 2023 Apr 24. Cancer Immunol Immunother. 2023. PMID: 37093243 Free PMC article. Clinical Trial.
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: ishikawa m. Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8. Int J Hematol. 2024. PMID: 38587692
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Nishiyama-Fujita Y, et al. Among authors: ishikawa m. Ann Med. 2022 Dec;54(1):1244-1254. doi: 10.1080/07853890.2022.2069280. Ann Med. 2022. PMID: 35486442 Free PMC article.
39 results